ESTRAGUARD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRAGUARD (ESTRAGUARD).
Estradiol, the active ingredient, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting estrogenic effects including endometrial growth, vasodilation, and bone protection.
| Metabolism | Primarily hepatic via CYP3A4 and CYP1A2; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates). |
| Excretion | Estradiol and its metabolites are primarily excreted in urine (approximately 90-95%), with about 5% excreted in feces via bile. Less than 10% is excreted unchanged. |
| Half-life | The terminal elimination half-life of estradiol is approximately 13-20 hours following transdermal administration, allowing for twice-weekly dosing. Oral estradiol has a shorter half-life of 2-4 hours due to first-pass metabolism. |
| Protein binding | Approximately 98% bound, primarily to sex hormone-binding globulin (SHBG) (30-50%) and albumin (30-50%). Unbound fraction is about 2%. |
| Volume of Distribution | Transdermal estradiol has a volume of distribution of approximately 1.2 L/kg, indicating extensive distribution into tissues. Oral estradiol has a Vd of about 1.4 L/kg. |
| Bioavailability | Oral: Approximately 2-10% due to extensive first-pass metabolism. Transdermal: 3-10% (systemic), but consistent delivery avoids first-pass. Vaginal: Absorption is variable; for local effects, systemic bioavailability is low (approximately 5% for cream), but for systemic replacement, vaginal ring achieves ~50% bioavailability. |
| Onset of Action | Transdermal: Symptom relief (e.g., hot flashes) typically occurs within 2-4 weeks. Oral: Onset of action is within 2-4 weeks for menopausal symptoms. Vaginal: Local effects (e.g., vaginal atrophy) may improve within 7-10 days. |
| Duration of Action | Transdermal: Duration of action is approximately 3-4 days, supporting twice-weekly application. Oral: Duration of action is about 24 hours, requiring daily dosing. Vaginal: Local effects last 24 hours for cream; ring provides 3 months of continuous release. |
0.1% cream: 2-4 g intravaginally once daily for 2 weeks, then 1-2 g once daily 1-3 times per week for maintenance. Estradiol vaginal ring: 2 mg releasing 7.5 mcg/24h, inserted vaginally every 90 days.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. GFR <30 mL/min: use with caution due to potential fluid retention. |
| Liver impairment | Child-Pugh class A/B: no adjustment. Child-Pugh class C: contraindicated due to reduced estradiol metabolism. |
| Pediatric use | Not indicated in pediatric patients. |
| Geriatric use | Initiate at lowest effective dose; use non-oral route if risk of thromboembolism. Monitor for endometrial hyperplasia if uterus intact; consider progestin coadministration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTRAGUARD (ESTRAGUARD).
| Breastfeeding | Estradiol is excreted in breast milk in small amounts; M/P ratio approximately 0.1–0.5. Estrogens may reduce milk production and quality; use during breastfeeding is not recommended due to potential adverse effects on the infant (e.g., gynecomastia, vaginal bleeding) and lack of safety data. |
| Teratogenic Risk | Estraguard (estradiol) is contraindicated in pregnancy. First trimester: Estrogens are associated with a risk of congenital anomalies including cardiovascular defects and urogenital malformations; also linked to vaginal adenosis and clear cell adenocarcinoma in female offspring with in utero DES exposure. Second and third trimesters: Continued exposure may increase risk of fetal reproductive tract abnormalities, low birth weight, and preterm delivery; no safe dose established; risk category X. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. In the Women’s Health Initiative (WHI) study, increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis were reported. In the Women’s Health Initiative Memory Study (WHIMS), increased risk of probable dementia was observed in postmenopausal women 65 years of age or older.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease (e.g., stroke, MI) or history thereof","Known or suspected pregnancy","Hepatic impairment or disease","Hypersensitivity to estradiol or any component"]
| Precautions | ["Increased risk of endometrial cancer; use with progestin in women with intact uterus","Increased risk of cardiovascular events (stroke, MI, DVT, PE)","Increased risk of probable dementia in women ≥65 years","Gallbladder disease","Hypertriglyceridemia","Retinal vascular thrombosis","Fluid retention","Hypocalcemia in pre-existing hypoparathyroidism","Exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas"] |
Loading safety data…
| Fetal Monitoring | If inadvertent use occurs during pregnancy: Perform detailed fetal anatomical ultrasound including cardiac evaluation. Monitor fetal growth with serial ultrasounds. Assess for signs of estrogen-related adverse effects. No routine monitoring recommended for lactating infants beyond standard pediatric care if brief exposure. |
| Fertility Effects | Estradiol may suppress ovulation in a dose-dependent manner, potentially reducing fertility; use as a contraceptive is not approved. Fertility may be impaired during therapy but is generally reversible upon discontinuation; no permanent adverse effect on fertility expected. |